文献速递技术与安全CT

N-(2,3-二羟丙基)氨甲酰侧链:碘对比剂相关药物不良反应复发的潜在重要因素

N-(2,3-dihydroxypropyl) carbamoyl side chain: a potentially significant factor for recurrent iodinated contrast medium-related adverse drug reactions.
PubMed 文献 · Eur Radiol · 2024-04-16

单中心回顾性研究纳入2133例有碘对比剂相关药物不良反应史并接受增强CT的患者,比较更换与不更换对比剂、共用与不共用氨甲酰侧链的复发率;更换对比剂及使用不同侧链对比剂均与复发率降低和降级率升高相关。

要点

  • 更换碘对比剂后按患者复发率10.4%低于不更换的28.4%,校正OR 0.27。
  • 使用不同氨甲酰侧链对比剂按检查复发率5.0%低于共用侧链的7.8%,OR 0.63。
  • 不同侧链组降级率95.6%高于共用侧链组93.3%,OR 1.51。

核心结论

  • 更换为具有不同氨甲酰侧链的碘对比剂可降低后续检查中药物不良反应的复发率及其严重程度。

研究设计与样本

  • 单中心回顾性研究纳入2133例有碘对比剂相关药物不良反应史并接受增强CT的连续患者,平均年龄56.1±11.4岁,男性1052例(49.3%),采用倾向性评分匹配和逆概率治疗加权分析。

诊断标准与关键数值

  • 按患者分析:更换对比剂组复发率10.4%(100/965) vs 不更换组28.4%(332/1168),校正OR 0.27(95%CI 0.21,0.34;p<0.001)。
  • 倾向性评分匹配后OR 0.29(95%CI 0.22,0.39;p<0.001),逆概率治疗加权后OR 0.28(95%CI 0.22,0.36;p<0.001)。
  • 按检查分析:更换组复发率5.5% vs 不更换组13.8%,OR 0.32(95%CI 0.27,0.37;p<0.001)。
  • 按检查分析:使用不同侧链组复发率5.0%(195/3938) vs 共用侧链组7.8%(79/1017),OR 0.63(95%CI 0.47,0.83;p=0.001)。
  • 按检查分析:不同侧链组降级率95.6%(3764/3938) vs 共用侧链组93.3%(949/1017),OR 1.51(95%CI 1.12,2.03;p=0.006)。

临床应用与阅片要点

  • 对有碘对比剂相关药物不良反应史的患者,更换为不同氨甲酰侧链的碘对比剂与复发率降低相关。
  • 使用不同氨甲酰侧链对比剂与复发不良反应严重程度降级率升高相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To determine whether switching to contrast media based on the sharing of N-(2,3-dihydroxypropyl) carbamoyl side chain reduces the recurrence of iodinated contrast media (ICM)-associated adverse drug reactions (ADRs).

MATERIALS AND METHODS: This single-center retrospective study included 2133 consecutive patients (mean age ± SD, 56.1 ± 11.4 years; male, 1052 [49.3%]) who had a history of ICM-associated ADRs and underwent contrast-enhanced CT examinations. The per-patient and per-exam-based recurrence ADR rates were compared between cases of switching and non-switching the ICM from ICMs that caused the previous ADRs, and between cases that used ICMs with common and different carbamoyl side chains from ICMs that caused the previous ADRs. Downgrade rates (no recurrence or the occurrence of ADR less severe than index ADRs) were also compared. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) analysis were additionally performed.

RESULTS: In per-patient analysis, switching of ICM showed a lower recurrence rate (switching, 10.4% [100/965] vs. non-switching, 28.4% [332/1168]), with the adjusted odds ratio (OR) of 0.27 (95% CI: 0.21, 0.34; p < 0.001). The result was consistent in PSM (OR, 0.29 [95% CI: 0.22, 0.39]; p < 0.001), IPTW (OR, 0.28 [95% CI: 0.22, 0.36]; p < 0.001), and in per-exam analysis (5.5% vs. 13.8%; OR, 0.32 [95% CI: 0.27, 0.37]; p < 0.001). There was lower per-exam recurrence (5.0% [195/3938] vs. 7.8% [79/1017]; OR, 0.63 [95% CI: 0.47, 0.83]; p = 0.001) and higher downgrade rates (95.6% [3764/3938] vs. 93.3% [949/1017]; OR, 1.51 [95% CI: 1.12, 2.03]; p = 0.006) when using different side chain groups.

CONCLUSION: Switching to an ICM with a different carbamoyl side chain reduced the recurrent ADRs and their severity during subsequent examinations.

CLINICAL RELEVANCE STATEMENT: Switching to an iodinated contrast media with a different carbamoyl side chain reduced the recurrent adverse drug reactions and their severity during subsequent examinations.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Kim PH, Suh CH, Jang EB, et al. N-(2,3-dihydroxypropyl) carbamoyl side chain: a potentially significant factor for recurrent iodinated contrast medium-related adverse drug reactions. Eur Radiol. 2024. PMID: 38625610. doi:10.1007/s00330-024-10730-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。